Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Azelastine (1) ·
Bimatoprost (1) ·
Brimonidine (1) ·
Ciprofloxacin (1) ·
Cyanocobalamin (vitamin B12) (1) ·
Dorzolamide (1) ·
Folic acid (folate, pteroylglutamic acid) (1) ·
Ketotifen (1) ·
Latanoprost (1) ·
Levofloxacin (1) ·
Medroxyprogesterone acetate (MPA) (1) ·
Methadone (1) ·
Moxifloxacin (1) ·
Olopatadine (1) ·
Tiotropium (1)
brand:
Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea) (1) ·
Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista (1) ·
Avelox (oral/IV brand discontinued US); Vigamox, Moxeza (ophthalmic) (1) ·
Cipro, Cipro XR, Ciloxan (ophthalmic) (1) ·
Dolophine, Methadose, Diskets (oral dispersible tablets for OTPs) (1) ·
Folvite; mostly generic (1) ·
Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix (1) ·
Lumigan (glaucoma), Latisse (eyelash growth) (1) ·
Many OTC and Rx; Nascobal (intranasal); generic injection (1) ·
Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal) (1) ·
Provera (oral), Depo-Provera (IM contraceptive), Depo-SubQ Provera 104 (SC) (1) ·
Spiriva, Spiriva Respimat (1) ·
Trusopt; with timolol as Cosopt (1) ·
Xalatan, Xelpros (1) ·
Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1)
classes:
[[:Category:Alpha-2_agonists|Alpha-2 adrenergic agonist]] (1) ·
[[:Category:Antibacterials|Antibacterial]] (3) ·
[[:Category:Antimuscarinics|Antimuscarinic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (2) ·
[[:Category:Bronchodilators|Bronchodilator]] (1) ·
[[:Category:Carbonic_anhydrase_inhibitors|Carbonic anhydrase inhibitor (topical)]] (1) ·
[[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (3) ·
[[:Category:Glaucoma_medications|Glaucoma medication]] (4) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (3) ·
[[:Category:Hematinics|Hematinic]] (2) ·
[[:Category:Hormonal_contraceptives|Hormonal contraceptive (Depo)]] (1) ·
[[:Category:Intranasal_antihistamines|Intranasal antihistamine]] (1) ·
[[:Category:Long-acting_muscarinic_antagonists|Long-acting muscarinic antagonist (LAMA)]] (1) ·
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (3) ·
[[:Category:NMDA antagonists|NMDA receptor antagonist]] (1) ·
[[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (4) ·
[[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]] (2) ·
[[:Category:Opioid analgesics|Opioid analgesic (full mu-agonist)]] (1) ·
[[:Category:Progestogens|Progestin (synthetic progestogen)]] (1) ·
[[:Category:Prostaglandin_analogs|Prostaglandin F2α analog]] (2) ·
[[:Category:Schedule II controlled substances|Schedule II controlled substance]] (1) ·
[[:Category:Sex_hormones|Sex hormone]] (1) ·
[[:Category:Vitamins|Vitamin]] (2)
mechanism:
None (11) ·
'"`UNIQ--vote-00000D7A-QINU`"' Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities'"`UNIQ--ref-00000D7B-QINU`"'. (1) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
'"`UNIQ--vote-0000004C-QINU`"', '"`UNIQ--vote-0000004D-QINU`"', '"`UNIQ--vote-0000004E-QINU`"' (1) ·
'"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1) ·
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"' (1) ·
'"`UNIQ--vote-000009BE-QINU`"', '"`UNIQ--vote-000009BF-QINU`"' (1) ·
'"`UNIQ--vote-00000B08-QINU`"', '"`UNIQ--vote-00000B09-QINU`"' (1) ·
'"`UNIQ--vote-00000CEF-QINU`"', '"`UNIQ--vote-00000CF0-QINU`"', '"`UNIQ--vote-00000CF1-QINU`"', '"`UNIQ--vote-00000CF2-QINU`"', '"`UNIQ--vote-00000CF3-QINU`"', '"`UNIQ--vote-00000CF4-QINU`"' (1) ·
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"' (1) ·
'"`UNIQ--vote-00000D9E-QINU`"', '"`UNIQ--vote-00000D9F-QINU`"', '"`UNIQ--vote-00000DA0-QINU`"' (1) ·
'"`UNIQ--vote-00000F1B-QINU`"', '"`UNIQ--vote-00000F1C-QINU`"', '"`UNIQ--vote-00000F1D-QINU`"', '"`UNIQ--vote-00000F1E-QINU`"', '"`UNIQ--vote-00000F1F-QINU`"' (1) ·
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"' (1) ·
'"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1) ·
'"`UNIQ--vote-00001286-QINU`"' (1) ·
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"' (1)
starting dose:
None (1) ·
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt) (1) ·
1 drop in the affected eye(s) once daily in the evening (1) ·
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime (1) ·
18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat) (1) ·
400 mg PO/IV once daily (1) ·
500-750 mg PO BID; 400 mg IV q8-12h (1) ·
500-750 mg PO/IV once daily (1) ·
Contraception: Depo-Provera 150 mg IM every 13 weeks; Depo-SubQ 104 mg SC every 12-13 weeks; oral cycling: 5-10 mg PO daily ×5-10 days for amenorrhea (1) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1) ·
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1)
preparations:
0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle (1) ·
0.01%, 0.03% ophthalmic solution (1) ·
0.025%, 0.035% ophthalmic solutions (1) ·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) ·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1) ·
0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) (1) ·
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) ·
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) ·
18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication) (1) ·
2% ophthalmic solution (Trusopt); 2%/0.5% fixed combination with timolol (Cosopt, Cosopt PF) (1) ·
2.5, 5, 10 mg oral tablets; Depo-Provera 150 mg/mL IM; Depo-SubQ Provera 104 mg/0.65 mL (1) ·
250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) ·
250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions (1) ·
400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1) ·
Tablets 5, 10, 40 mg (40 mg dispersible restricted to OTPs); oral concentrate 10 mg/mL; oral solution 1, 2, 10 mg/mL; injection 10 mg/mL (1)
fda max:
1 drop per eye q8-12h (1) ·
1 drop/eye/day (more frequent dosing reduces efficacy) (1) ·
1 mg/d typical Rx; higher in specific indications (1) ·
2 sprays/nostril BID (1) ·
400 mg/d (1) ·
750 mg/d (1) ·
Indication-specific (1) ·
No formal hard ceiling; in MOUD maintenance, doses typically remain at or below 120 mg/day with higher doses reserved for documented under-treatment after careful clinical assessment (1) ·
No strict ceiling; water-soluble vitamin, low toxicity (1) ·
Once daily (Pataday 0.7%); BID (other ophthalmic) (1) ·
One dose per day (1) ·
One drop per eye per day (1) ·
TID per eye (2) ·
~1500 mg/d (oral); 1200 mg/d (IV) (1)
routes: (Click arrow to add another value)
onset:
15 minutes (1) ·
Bronchodilation 30 minutes; steady-state at 1-2 weeks (1) ·
Contraceptive within 24 hours if given in first 5 days of cycle; otherwise backup for 7 days (1) ·
Hematologic response within days (1) ·
Hours (3) ·
IOP lowering at 1 hour; max at 2-3 hours (1) ·
IOP lowering at 2 hours; max at 4 hours (1) ·
IOP lowering at 3-4 hours; maximum at 8-12 hours (1) ·
IOP lowering at 4 hours, maximum at 8-12 hours; eyelash effect after 2 months (1) ·
Oral analgesic effect 30-60 minutes; opioid-withdrawal suppression 30 minutes (oral); IV ~10 minutes (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) ·
Symptom relief within 30-60 minutes (1) ·
Within minutes (1)
duration:
12 hours (1) ·
24 hours (4) ·
24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) ·
24 hours (long receptor dissociation half-life from M3) (1) ·
8-12 hours (3) ·
8-12 hours (TID dosing needed) (1) ·
Analgesic effect 4-8 hours (much shorter than half-life would suggest, due to receptor kinetics); MOUD effect (opioid withdrawal suppression) 24-36 hours per single daily dose (1) ·
Depot IM 13 weeks (designed); often persists longer (1) ·
N/A (replacement) (2)
halflife:
None (1) ·
4 hours'"`UNIQ--ref-00000938-QINU`"' (1) ·
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
~0.5 hours plasma; tissue retention longer (1) ·
~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) ·
~17 minutes (free acid, the active form, in aqueous humor)'"`UNIQ--ref-00000417-QINU`"' (1) ·
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"' (1) ·
~25-44 hours plasma; receptor kinetics drive the once-daily duration'"`UNIQ--ref-000009C0-QINU`"' (1) ·
~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1) ·
~3 hours'"`UNIQ--ref-000010D1-QINU`"' (1) ·
~4 months in erythrocytes (carbonic anhydrase binding in red cells; not relevant to topical IOP duration)'"`UNIQ--ref-00000B0A-QINU`"' (1) ·
~45 minutes (free acid in aqueous humor)'"`UNIQ--ref-00000DA1-QINU`"' (1) ·
~50 days (Depo-Provera; long depot release)'"`UNIQ--ref-00000F20-QINU`"' (1) ·
~6 days (plasma); hepatic stores last 3-5 years (1) ·
~6-8 hours'"`UNIQ--ref-00000CF5-QINU`"' (1)
bioavailability:
High (oral) (1) ·
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"' (1) ·
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"' (1) ·
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) ·
Oral ~90%; depot IM essentially 100% over the dosing interval'"`UNIQ--ref-00000F21-QINU`"' (1) ·
Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) ·
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"' (1) ·
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) ·
~70-85% (oral, high relative to other opioids) (1) ·
~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' (1) ·
~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"' (1)
pregnancy:
None (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Contraindicated in known pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; LABA/LAMA strategies in pregnancy generally favor agents with the most reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives, though systemic exposure is low.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (2) ·
OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US (1) ·
OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) ·
OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) ·
OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) ·
OTC in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US (5) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bone mineral density loss with prolonged use (≥2 years; partially reversible after discontinuation)'"`UNIQ--ref-00000F22-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis'"`UNIQ--ref-00000CF7-QINU`"' (1)
Showing below up to 15 results in range #1 to #15.